“We expect to share detailed results later this year.”

In context

“injectable semaglutide or tirzepatide then switched to orforglipron or placebo. As shown on slide 16, orforglipron helped people maintain weight loss that they had achieved on injectable therapies, and the study met all primary and secondary endpoints. People who switched from semaglutide to orforglipron maintained their previously achieved weight loss, with an average difference of just 0.9 kilograms. This suggests that as an oral GLP-1 therapy, orforglipron may provide similar weight loss maintenance as the maximum tolerated dose of injectable GLP-1 therapy semaglutide. As expected, those who switched from maximum tolerated doses of the dual GIP GLP-1 agonist tirzepatide to oral GLP-1 inhibitor maintained much of their weight, although with a higher average difference of five kilograms. We expect to share detailed results later this year. Other orforglipron updates since our last call include submission of orforglipron to the FDA for treatment of obesity, with approval expected in Q2 of this year, submission of orforglipron for obesity and for type two diabetes in a number of other countries around the world, initiation of orforglipron phase three cardiovascular outcomes trials, and initiation of orforglipron phase three for treatment of peripheral artery disease. We look forward to completing the US regulatory submission of orforglipron for type two diabetes later this year after the Achieve IV trial is complete. We also announced new data for our GIP GLP-1 glucagon triple agonist, retreutide. In the first phase three trial to complete, TRIUMPH-4, we evaluated retreutide in adults with obesity and knee osteoarthritis. Par”